Summary The clinical efficacy of solid tumor CAR-T therapies hinges on overcoming metabolic barriers within the tumor microenvironment. This article explores how tracking CD8+ T cell metabolic reprogramming, glucose competitive kinetics, and cytokine secretion feedback can guide the precise engineering of persistence-enhanced cell therapies.   While Chimeric Antigen Receptor (CAR) T-cell...